• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Aston Particle Technologies gets £1 million in funding

Aston University spin out Aston Particle Technologies (APT) has closed a £1 million funding round according to lead investor DSW Ventures. The funding will be used for scale up of APT’s isothermal dry particle coating (iDPC) technology, which DSW said is useful for high dose DPI formulations among other uses. DSW explained that the expanded cGMP capacity is necessary “to accelerate partnerships with pharmaceutical groups and contract development and manufacturing organizations, as well as to expand its product development and commercial teams” and noted that APT has used the iDPC technology to formulate an inhaled anti-fungal which is its lead compound.

APT’s leadership includes former Pfizer Head of Inhalation and Devices Product Development Ian Smith and former GSK Head of the Respiratory New Product Introduction Centre of Excellence David Wyatt. Wyatt commented, “This new partnership will enable us to build with confidence upon the foundation provided by Aston University and Innovate UK to commericalize iDPC at scale and to accelerate the development of innovative medicines.”

DSW Ventures Investment Executive Emma Cassidy said, “We believe that APT’s technology is truly innovative and will change the way drugs are formulated and developed. The simplicity of the technology and its ability to formulate drugs that previously could not be made in a practical or effective way is truly exciting. We look forward to working with such an experienced and dedicated management team, and have high hopes for the future of the business.”

Read the DSW Ventures press release.

Share

published on May 18, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews